Sign in
Enrolling by invitationNo phase

Platelet Transfusion and Repeat TEG-PM in Patients With Severe TBI on Antiplatelet Therapy (Repeat TEG-PM)

Key facts

Who runs it
Lancaster General Hospital
Where
Lancaster, United StatesSee the site
Trial code
Status
Enrolling by invitation
People taking part
225 people, planned
Started
1 Dec 2023
Expected to end
Nov 2027
Type of study
Observational, 2 groups
Treatments tested
  • Repeat Thromboelastography with Platelet Mapping
Record updated
29 October 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Patients ≥ 18 years of age who present with TICH meeting Brain Injury Guidelines (BIG) 2 or 3 head bleed criteria
  • Currently on antiplatelet medication on admission
  • Must have taken this antiplatelet medication within the past 48 hours prior to presentation
  • Patients who have AA and/or ADP inhibition of 70% or greater and Maximum Amplitude (MA) <50 will then receive a platelet transfusion and a repeat TEG-PM 1hr after transfusion
  • Patients with a TICH who are 18 years of age or older

Who cannot take part

  • Do not know the time of their last antiplatelet medication dose
  • Patients with concomitant long bone fractures or solid organ injuries
  • Abbreviated Injury Scale (AIS) >1 in body regions other than head because of concomitant long bone fracture or solid organ injury
  • Have a known bleeding diatheses
  • Under 18 years of age
  • Under 18 years of age
  • Current therapeutic anticoagulation use
  • Patients or their proxy who are unable to provide consent

Where in United States

  • Penn Medicine Lancaster General HealthLancaster, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

The aim of this study is to see if administering platelets (cells in our blood that stop or prevent bleeding) results in improved platelet function and slows/stops the progression of a head bleed for patients who have a traumatic head bleed and are on antiplatelet therapy (medications that stop blood cells from forming a blood clot) prior to admission.

The 2 groups in the trial

  • Repeat TEG-PM

    Will receive a repeat TEG-PM after platelet transfusion based on inclusion criteria.

    Treatment: Repeat Thromboelastography with Platelet Mapping

  • No Repeat TEG-PM

    Not eligible to be consented; will proceed with normal course of treatment.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Platelet Transfusion and Repeat Thromboelastography With Platelet Mapping (TEG-PM) in Patients With Severe Traumatic Brain Injuries (TBI) on Antiplatelet Therapy
Record updated
29 October 2025